Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma

• DOI: 10.1093/annonc/mdx684
• Publication Date: 2017-10-19T19:09:16Z
• Authors: Y.L. Kwong; S.J. Kim; E. Tse; S.Y. Oh; J.Y. Kwak; H.S. Eom; Y.R. Do; Y.C. Mun; S.R. Lee; H.J. Shin; C. Suh; S.S. Chuang; Y.S. Lee; S.T. Lim; K. Izutsu; R. Suzuki; T. Relander; F. d’Amore; N. Schmitz; A. Jaccard; W.S. Kim
• Keywords: Chemoradiotherapy; T-Cell Lymphoma

In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with anthracycline-containing regimens, which have since considered ineffective. The role of CCRT comparison approaches employing nonanthracycline-containing chemotherapy (CT) and sequential radiotherapy (RT) such patients remains be defined.Three hundred three untreated (207 men, 96 women; median age: 51, 18-86 years) NK/T-cell lymphoma who received regimens were collected from an international consortium retrospectively analyzed. Treatment included single modality (CT RT), modalities + RT; RT CT) (CCRT; CT). impact clinicopathologic parameters types treatment on complete response (CR) rate, progression-free-survival (PFS) overall-survival (OS) was evaluated.For CR, (P = 0.027), prognostic index for (PINK) 0.026) initial 0.011) significant factors multivariate analysis. On Cox regression analysis, ECOG performance score 0.021) PINK-EBV DNA (PINK-E) 0.002) significantly impacted PFS; whereas 0.008) < 0.001) OS. For comparing ± CT RT, (n 190) similar 54) all evaluated except two features (higher proportion undetectable circulating EBV diagnosis lower PINK-E scores). Despite more favorable pre-treatment characteristics, CR PFS OS comparable analyses.In lymphomas, when effective chemotherapeutic used, gave outcome.